MCRB — Seres Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $124.58m
- $98.16m
- $126.33m
- 20
- 37
- 19
- 15
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -70.3 | -89.1 | -65.6 | -250 | -114 |
Depreciation | |||||
Non-Cash Items | 10.8 | 12.1 | 24.8 | 33.1 | 49.1 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -24.6 | -23.2 | 41.5 | -18.4 | -59 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -76.5 | -93.6 | 6.69 | -229 | -117 |
Capital Expenditures | -1 | -0.591 | -9.57 | -9.82 | -7.97 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -29.5 | -158 | 73.7 | 92.2 | 18.6 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -30.5 | -159 | 64.1 | 82.4 | 10.6 |
Financing Cash Flow Items | -0.425 | 19.9 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 86.2 | 303 | 1.18 | 130 | 71.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -20.8 | 50.9 | 72 | -16.8 | -35.1 |